The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Interferon-Alpha Produces Sustained Cytogenetic Responses in Chronic Myelogenous Leukemia: Philadelphia Chromosome-Positive Patients
Abstract
OBJECTIVES: To evaluate the frequency and the course of complete cytogenetic responses in interferon-alpha (IFN-alpha)-treated patients with chronic myelogenous leukemia. DESIGN: Two prospective trials in consecutive patients. SETTING: A major tertiary cancer center. PATIENTS: Ninety-six consecutive patients with chronic myelogenous leukemia with disease duration of less than 1 year. INTERVENTION: Patients received partially pure IFN-alpha intramuscularly, from 3 to 9 million U/d (51 patients) or recombinant IFN-alpha 2a (Roferon, Hoffmann-LaRoche, Inc., Nutley, New Jersey), 5 million U/m2 body surface area daily (45 patients). MEASUREMENTS: Hematologic and cytogenetic tests were administered. MAIN RESULTS: Seventy of the patients (73%) achieved hematologic remission (95% CI, 63% to 81%), and 18 (19%) had complete suppression of the Philadelphia chromosome on at least one cytogenetic test. A complete cytogenetic response was induced in 7 of 51 or 14% (CI, 6% to 26%) of the patients treated with the partially pure IFN-alpha and in 11 of 45 or 24% (CI, 13% to 40%) of the patients treated with recombinant IFN-alpha 2a. The difference in complete cytogenetic response between the two groups was 10.7% (CI, - 5% to 26%; P greater than 0.2). Eleven patients had durable, ongoing, complete cytogenetic responses from 6 to more than 45 months (median, more than 30 months). CONCLUSION: This study was the first to show sustained, complete cytogenetic responses in a subset of patients with chronic myelogenous leukemia treated with single-agent therapy. The nature of this remission, that is, whether it depends on continuous therapy, requires further study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alpha Interferon for Induction of Remission in Hairy-Cell Leukemia
Quesada, J. R., Reuben, J., Manning, J. T., Hersh, E. M., & Gutterman, J. U. (1984) · New England Journal of Medicine · doi:10.1056/nejm198401053100104 · Cited by 820
Self-citationTalpaz, M., Kantarjian, H. M., McCredie, K., Trujillo, J. M., Keating, M. J., & Gutterman, J. U. (1986) · New England Journal of Medicine · doi:10.1056/nejm198604243141701 · Cited by 647
Self-citationGUTTERMAN, J. U., BLUMENSCHEIN, G. R., ALEXANIAN, R., YAP, H.-Y., BUZDAR, A. U., CABANILLAS, F., HORTOBAGYI, G. N., HERSH, E. M., RASMUSSEN, S. L., HARMON, M., et al. (1980) · Annals of Internal Medicine · doi:10.7326/0003-4819-93-3-399 · Cited by 497
Self-citationLeukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia
Talpaz, M., McCredie, K., Mavligit, G., & Gutterman, J. (1983) · Blood · doi:10.1182/blood.v62.3.689.689 · Cited by 336
Self-citationClinical investigation of human alpha interferon in chronic myelogenous leukemia
Talpaz, M., Kantarjian, H., McCredie, K., Keating, M., Trujillo, J., & Gutterman, J. (1987) · Blood · doi:10.1182/blood.v69.5.1280.1280 · Cited by 328
Self-citationRenal cell carcinoma: antitumor effects of leukocyte interferon.
Quesada, J. R., Swanson, D. A., Trindade, A., & Gutterman, J. U. (1983) · PubMed · Cited by 314
Self-citationALLOGENEIC BONE-MARROW TRANSPLANTATION FOR CHRONIC MYELOGENOUS LEUKAEMIA
Speck, B., Bortin, M., Champlin, R., Goldman, J., Herzig, R., Mcglave, P., Messner, H., Weiner, R., & Rimm, A. (1984) · The Lancet · doi:10.1016/s0140-6736(84)92179-2 · Cited by 259
Chronic myelogenous leukemia: recent advances
Champlin, R., & Golde, D. (1985) · Blood · doi:10.1182/blood.v65.5.1039.1039 · Cited by 256
Chronic Myelogenous Leukemia — New Concepts
Koeffler, H. P., & Golde, D. W. (1981) · New England Journal of Medicine · doi:10.1056/nejm198105143042004 · Cited by 240
Kantarjian, H., Smith, T., McCredie, K., Keating, M., Walters, R., Talpaz, M., Hester, J., Bligham, G., Gehan, E., & Freireich, E. (1985) · Blood · doi:10.1182/blood.v66.6.1326.1326 · Cited by 215
Self-citation
Cited by
Baccarani, M., Cortes, J., Pane, F., Niederwieser, D., Saglio, G., Apperley, J., Cervantes, F., Deininger, M., Gratwohl, A., Guilhot, F., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.0779 · Cited by 1,291
Self-citationCytokine therapeutics: lessons from interferonalpha.
Gutterman, J. U. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.4.1198 · Cited by 703
Self-citationGratwohl, A., Hermans, J., Goldman, J., Arcese, W., Carreras, E., Devergie, A., Frassoni, F., Gahrton, G., Kolb, H., Niederwieser, D., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03030-x · Cited by 646
(1994) · New England Journal of Medicine · doi:10.1056/nejm199403243301204 · Cited by 577
The interferons. Mechanisms of action and clinical applications
Baron, S. (1991) · JAMA · doi:10.1001/jama.266.10.1375 · Cited by 569
Metadata
- Authors
- Talpaz, M., Kantarjian, H., Kurzrock, R., Trujillo, J. M., & Gutterman, J. U.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 1991-04-01
- Volume
- 114
- Issue
- 7
- Pages
- 532-538
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2089697181
- Cited by
- 382
- References
- 17
- FWCI
- 23.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Interferon-Alpha Produces Sustained Cytogenetic Responses in Chronic Myelogenous Leukemia: Philadelphia Chromosome-Positive Patients. https://app.cochat.ai/papers/10.7326/0003-4819-114-7-532
- The paper
- Talpaz, M., Kantarjian, H., Kurzrock, R., Trujillo, J. M., & Gutterman, J. U. (1991). Interferon-Alpha Produces Sustained Cytogenetic Responses in Chronic Myelogenous Leukemia: Philadelphia Chromosome-Positive Patients. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-114-7-532
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.